Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2011 1
2012 1
2013 1
2014 5
2015 5
2016 5
2018 2
2019 7
2020 17
2021 7
2022 9
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: bourlon mt. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Motzer RJ, et al. Among authors: bourlon mt. Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7. Lancet Oncol. 2022. PMID: 35688173 Free PMC article. Clinical Trial.
Women, power, and cancer: a Lancet Commission.
Ginsburg O, Vanderpuye V, Beddoe AM, Bhoo-Pathy N, Bray F, Caduff C, Florez N, Fadhil I, Hammad N, Heidari S, Kataria I, Kumar S, Liebermann E, Moodley J, Mutebi M, Mukherji D, Nugent R, So WKW, Soto-Perez-de-Celis E, Unger-Saldaña K, Allman G, Bhimani J, Bourlon MT, Eala MAB, Hovmand PS, Kong YC, Menon S, Taylor CD, Soerjomataram I. Ginsburg O, et al. Among authors: bourlon mt. Lancet. 2023 Dec 2;402(10417):2113-2166. doi: 10.1016/S0140-6736(23)01701-4. Epub 2023 Sep 26. Lancet. 2023. PMID: 37774725 Review. No abstract available.
Development of PARP inhibitors in advanced prostate cancer.
Bourlon MT, Valdez P, Castro E. Bourlon MT, et al. Ther Adv Med Oncol. 2024 Jan 9;16:17588359231221337. doi: 10.1177/17588359231221337. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38205078 Free PMC article. Review.
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT. Castro-Alonso FJ, et al. Among authors: bourlon mt. Oncology (Williston Park). 2023 Jun 12;37(6):256-261. doi: 10.46883/2023.25920998. Oncology (Williston Park). 2023. PMID: 37343207 Free article.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Bassanelli M, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Montironi R, Battelli N, Porta C. Santoni M, et al. Among authors: bourlon mt. Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27. Target Oncol. 2023. PMID: 37369815
Creative Approaches to Global Cancer Research and Control.
Rositch AF, Loffredo C, Bourlon MT, Pearlman PC, Adebamowo C. Rositch AF, et al. Among authors: bourlon mt. JCO Glob Oncol. 2020 Jul;6:4-7. doi: 10.1200/GO.20.00237. JCO Glob Oncol. 2020. PMID: 32716656 Free PMC article. No abstract available.
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Del Tejo V, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C. McGregor B, et al. Among authors: bourlon mt. Eur Urol Oncol. 2023 Jun;6(3):339-348. doi: 10.1016/j.euo.2023.01.012. Epub 2023 Feb 25. Eur Urol Oncol. 2023. PMID: 36842942 Free article.
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Porta C, Bamias A, Zakopoulou R, Myint ZW, Cavasin N, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, DE Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Mollica V, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Zabalza IO, Rizzo A, Bisonni R, Pierantoni F, Sorgentoni G, Monteiro FS, Battelli N, Buti S, Santoni M. Porta C, et al. Among authors: bourlon mt. Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7. Minerva Urol Nephrol. 2023. PMID: 37530662 Free article.
Global Oncology Authorship and Readership Patterns.
Bourlon MT, Jiménez Franco B, Castro-Alonso FJ, Bourlon C, Matar CF, Gunn E, Ginsburg O, Lopes G, Segelov E. Bourlon MT, et al. JCO Glob Oncol. 2022 Mar;8:e2100299. doi: 10.1200/GO.21.00299. JCO Glob Oncol. 2022. PMID: 35258989 Free PMC article.
79 results